AbbVie (ABBV) Completes Acquisition of Nimble Therapeutics

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Nimble Therapeutics. With the completion of the acquisition, Nimble is now a part of AbbVie.

Nimble's lead asset is an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis. Additionally, Nimble's peptide synthesis, screening, and optimization platform uses proprietary technology to help drive rapid discovery and optimization of oral peptide candidates for a range of targets.

"With the acquisition now complete, we are excited to expand our immunology pipeline to include Nimble's novel oral peptide assets and look forward to integrating this proprietary technology into our R&D capabilities," said Jonathon Sedgwick, Ph.D., senior vice president and global head of discovery research, AbbVie. "We are pleased to welcome the talented team at Nimble who share our commitment to elevating the standard of care for people living with autoimmune diseases."

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• HUB Cyber Security receives Nasdaq deficiency notice over market value
• Heidi L. O'Neill resigns from Lithia Motors board